A Randomized, Placebo Controlled, Double-blind, Phase 4 Study to Evaluate Efficacy and Safety of Triple Anti-platelet Therapy Compared With Dual Antiplatelet Therapy in Patients Treated With DES for Coronary Artery Disease

Trial Profile

A Randomized, Placebo Controlled, Double-blind, Phase 4 Study to Evaluate Efficacy and Safety of Triple Anti-platelet Therapy Compared With Dual Antiplatelet Therapy in Patients Treated With DES for Coronary Artery Disease

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 18 Nov 2015

At a glance

  • Drugs Cilostazol (Primary) ; Aspirin; Clopidogrel
  • Indications Angina pectoris; Embolism and thrombosis; Ischaemia
  • Focus Adverse reactions
  • Acronyms DECREASE-PCI
  • Most Recent Events

    • 13 Nov 2015 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 24 Jul 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 23 Jul 2014 Planned End Date changed from 1 Apr 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top